Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation

Objective : comparative pharmacoeconomic analysis of iron preparations for intravenous infusion in the treatment deficiency anemia (IDA) within concept patient blood management program. Material and methods . A retrospective study was carried out using efficiency, costs costeffectiveness. Comparison oligoisomaltose [III] (Monofer) carboxymaltose (Ferinject®) out. Results. In general, Monofer Ferinject® are characterized by comparable efficacy terms hematological response. Using a dosiological model an increase hemoglobin levels over time with drugs under consideration frequencies response were calculated (Monofer – 79%, 70%). The cost treating one average body weight 88.3 kg initial level 100 g/l 13,097 rubles 15,681 Ferinject®. values cost-effectiveness indicator accordance criterion effectiveness amounted to 16,578 22,402 (Ferinject®), which allows consider as strictly preferred. With colorectal surgery example, it has been shown that use this drug patients can reduce total (in particular, reducing required number portions red cells). Conclusion wider IDA reasonable economic advantages. preparation is preferred relation iron.